Trial: 201710005

NRG-GY009: A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab (IND #134427) versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer.

Phase

II/III

Principal Investigator

Thaker, Premal

Disease Site

Other Female Genital; Ovary; Soft Tissue

Learn more about this study at: clinicaltrials.gov